Attention! First Antihypertensive with a Novel Mechanism in Nearly 40 Years!

01 Product Introduction

The trillion-yuan red ocean market is ushering in a "second spring".

In March 2024, aprocitentan (TRYVIO™), a dual endothelin receptor antagonist developed by Idorsia, was approved, breaking a nearly 40-year dry spell for new-mechanism antihypertensive drugs approved by the FDA. In May 2026, baxdrostat of AstraZeneca became the world’s first aldosterone synthase inhibitor (ASI) to gain approval. Zilebesiran, an siRNA drug co-developed by Roche and Alnylam, is advancing into a Phase III trial enrolling ten thousand participants, with a marketing application submission expected in 2028.

Within just a few years, multiple agents with novel mechanisms of action have come to the market. Chinese pharmaceutical enterprises including Salubris, Hengrui, Innovent, Qilu Pharmaceutical and Bowo Pharma have long entered this arena for strategic layout.

Amid this wave of new drugs, aprocitentan (trade names: TRYVIO™ / JERAYGO™, CAS No.: 1103522-45-7), the world’s first approved dual endothelin receptor antagonist (ERA), stands out as the frontrunner.

Molecular Formula：C₁₆H₁₄Br₂N₆O₄S

Molecular Weight：546.19

Chemical Name:：Sulfamide,N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]

Core Highlights

By antagonizing both endothelin A (ETA) and endothelin B (ETB) receptors simultaneously, aprocitentan blocks the vasoconstrictive effect of endothelin-1 (ET-1), thereby effectively lowering blood pressure. It does not act on the central nervous system and features a mechanism completely distinct from existing antihypertensive agents, offering a brand-new therapeutic option for patients with resistant hypertension.

Market Outlook

Resistant hypertension accounts for approximately 10% of all hypertensive patients, whose blood pressure fails to reach the target even when treated with three or more antihypertensive drugs at optimal doses. Data from the PRECISION Phase III clinical trial shows that when added to at least three background antihypertensive medications, aprocitentan significantly reduces 24-hour blood pressure in patients with resistant hypertension. It delivers particularly prominent control of nocturnal blood pressure and improves arteriosclerosis as well as salt-sensitive hypertension. Boasting substantial projected peak global sales, it is regarded as the next blockbuster in the cardiovascular field.

02 Patent Analysis: Long-Term Patent Protection, Now Is the Right Time for Strategic Layout

Analysis: The core compound patent of aprocitentan enjoys a relatively long protection period (expiring around 2043), so generic drugs cannot come to market in the short term. Nevertheless, initiating impurity research and process development from now on represents the optimal opportunity for strategic preparation for the future. Special attention should be paid to process complexity and polymorph control. The originator has filed multiple crystal-form patents; furthermore, its synthetic route poses challenges including multi-step reactions and selectivity control. These factors constitute technical barriers as well as entry points for our services.

03 Impurity Profile Analysis: Complex Synthetic Route with Impurity Control as a Core Challenge

The aprocitentan molecule contains sensitive moieties including pyrimidine ring, sulfonamide, brominated aromatic ring and ethoxy bridge. Its lengthy multistep synthetic route renders impurity control the biggest bottleneck for genericdrug development. Based on originator patents and published literature, four major categories of critical impurities are summarized below:

l Processrelated impurities (introduced via starting materials & reaction byproducts)

l API degradation impurities (stabilityindicating)

l Potential genotoxic impurities

l Chiral impurities

The aprocitentan molecule itself has no chiral centers. Attention shall nevertheless be paid to chiral impurities originating from starting materials or intermediates, as well as chiral impurities arising in combination regimens with SGLT2 inhibitors (SGLT2 inhibitors used in combination therapies generally contain chiral centers).

04 What We Can Offer — One-Stop Custom Synthesis Service for Aprocitentan

Backed by a PhD-led synthesis team, an in-house preparation department and a complete suite of analytical instruments (400 MHz NMR, LC-MS, preparative HPLC/SFC, etc.), we deliver the following solutions:

✅  High-purity impurity reference standards (purity ≥95%, supplied with COA, MS, NMR and HPLC spectra)

✅ Intermediate & API process development

✅ Custom synthesis services

Why Partner with Us?

✓ Expert Team: Composed of PhDs and Masters with extensive working experience in pharmaceutical enterprises and CROs.

✓ Full In-House Instrumentation: Proprietary NMR, mass spectrometry and preparative-HPLC equipment; no external outsourcing required.

✓ Competitive Pricing: Our pricing is favorable compared with peers for equivalent products.

✓ Proven Track Record: We have supplied impurity reference standards for numerous generic-drug manufacturers.

05 Take Action Now

Aprocitentan’s compound patent expires around 2043. Despite the long patent term, it features complex synthetic pathways, high-difficulty impurity control, high research thresholds and long development cycles. Now is the ideal window for advance layout of impurity investigation and process development. We have commenced synthesis of relevant aprocitentan impurities and welcome your inquiries.

QCS holds ANAB ISO 17034 accreditation. Our production and characterization of reference materials comply with international competency requirements for reference-material producers, generating data with international mutual-recognition validity to support regulatory submissions to NMPA, EMA, FDA and other authorities.